

Hyperpolarization-activated cyclic nucleotide-gated gene signatures and poor clinical outcome of cancer patient

Nam Nhut Phan¹, Tung Thanh Huynh^{1,2}, Yen-Chang Lin¹

¹Graduate Institute of Biotechnology, Chinese Culture University, Taipei, Taiwan; ²NTT Institute of Hi-Technology, Nguyen Tat Thanh University, Ho Chi Minh City, Vietnam

Contributions: (I) Conception and design: NN Phan, TT Huynh; (II) Administrative support: None; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: NN Phan; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Dr. Yen-Chang Lin, PhD. Graduate Institute of Biotechnology, Chinese Culture University, Taipei, Taiwan. Email: lyc10@ulive.pccu.edu.tw; lycnthu@gmail.com.

Background: we investigated the mRNA expression of hyperpolarization-activated cyclic nucleotide-gated genes (HCN1-4) in multiple types and subtypes of cancers.

Methods: We performed a meta-analysis of public microarray data from Oncomine and NextBio Research databases to discover the mRNA expression level of HCN1-4 in cancers. Survival analysis was also used to investigate the correlation between overexpression of HCN gene family with overall survival rate of cancer patients using Kaplan-Meier Plotter database and PROGene V2 database.

Results: HCN genes (HCN1-4) over-expression and under-expression in multiples types of cancers such as CNS and brain cancer, breast cancer, colorectal cancer, melanoma, and lymphoma were found. HCN1 was significantly correlated with low overall survival of breast cancer [hazard ratio (HR) =7.42, P=0.0019] and colorectal cancer (HR =1.66, P=0.0071) patients. The lower survival rates of lung cancer (HR =2.5, P= 0.0107), kidney cancer (HR =1.1, P=0.004) and gastric cancer (HR =1.33, P=0.0037) patients were significantly correlated with the expression of HCN2. HCN3 was significantly correlated to lower survival rates of breast cancer (HR =1.65, P=0.0016), and kidney cancer (HR =1.17, P=0.0049). HCN4 was highly correlated with the lower survival rates of breast cancer of gastric cancer (HR =1.25, P=0.022), lung cancer (HR =5.37, P=0.0433) and ovarian cancer (HR =13.58, P=0.0426).

Conclusions: These data suggested that HCN genes (HCN1-4) are likely to be potential candidates for cancer diagnosis and prognosis.

Keywords: Hyperpolarization-activated cyclic nucleotide-gated channel (HCN channel); cancers; Oncomine; overall survival; diagnosis; prognosis

Submitted Mar 30, 2017. Accepted for publication Jul 10, 2017.

doi: 10.21037/tcr.2017.07.22

View this article at: <http://dx.doi.org/10.21037/tcr.2017.07.22>

Introduction

Cancer is the leading cause of death all over the globe in recent decades. According to WHO, there were 8.2 million people who died from cancer in the year 2012, and in the next two decades this figure will grow to around 22 million (1). Until now, only 30% of cancers could be prevented (1). Commonly, cancer patients would undergo surgery synergistically with chemotherapy and/or radiotherapy,

which is painful, and has high mortality rate. According to the U.S. National Cancer Institute, around 200 cancer drugs are commercialized in the market. Nevertheless, researchers in cancer field are still looking to develop new anti-cancer drugs with more specificity and high efficiency (2).

Hyperpolarization-activated cyclic nucleotide-gated (HCN) channel is one of hundreds of intra-membrane ion channels involved in ion transport. HCN channels are




Figure 1 PRISMA 2009 flow diagram. The flow diagram shows screening process and selection criteria for suitable studies of the meta-analysis (21).

encoded by four genes, namely HCN1, HCN2, HCN3 and HCN4 (3). These four genes are predominantly localized and expressed in the heart and the central nervous system (3,4). HCN channels are activated by hyperpolarization, and which permit Na^+ and K^+ to flow inward to the cell (5). HCN channels' main physiological functions are in the heart (6) and the nervous system (4). HCN genes were found to play a role in arrhythmogenic disease and neurological disease (7). The pharmacological properties of these ion channels in cancer are relatively unknown.

Oncomine is a web-based database, which contains more than 700 independent datasets with an estimated 90,000 microarray trials (8,9). The use of Oncomine in several publications confirmed it is a reliable source of clinical datasets (10-16). Oncomine standardizes and organizes the datasets of public cancer microarray data into different cancer types and subtypes (8,9).

NextBio Research database (Illumina INC.) is a web-based platform containing microarray data of more than 20,000 published studies. This online database was introduced by Giovanni Coppola in his book in 2013 (17) and has been used in previous studies (18,19).

In this study, data mining of Oncomine and NextBio Research database was performed to conduct a meta-analysis of HCN gene expression across multiple types and subtypes of cancer. In addition, analysis of survival rate of cancer patients and HCN gene expression was conducted to investigate how these expressions affect the overall survival of cancer patients in the 3 and 5 years' period.

Methods

Data mining

A meta-analysis was performed to analyze the mRNA expression level of HCN gene family in clinical cancer specimens following PRISMA guidelines (20,21) (Figure 1, Tables S1-S9).

HCN gene (HCN1-4) expression within 17 cancer types was investigated. The mRNA expression of HCN genes in cancerous tissues was grouped by origin of tissue and then compared to normal tissue. Oncomine (www.oncomine.org) and NextBio Research database (<https://www.nextbio.com>) were used to analyze the mRNA expression of HCN gene family in clinical cancer tissues (22).

Database search strategy

In this study, the cancer *vs.* normal filter was chosen, which only displayed datasets examining HCN gene mRNA expression in the same origin of tissue. In order to be included in the study, all the data from Oncomine and NextBio research database must satisfy the following threshold: $P < 0.05$, a fold change > 1.5 and a gene rank percentile $< 10\%$ (only applicable to data from Oncomine) (9) (Figure 1). Statistical analyses were conducted with Oncomine and NextBio Research default algorithms such as P values, two-tailed Student's *t*-test, and multiple testing corrections. In total, there were 120 studies with 8,471 samples included in this study. All the searches were performed from December 2015 to December 2016.

Survival analysis

The correlation between HCN gene family and overall survival rate was analyzed using Kaplan-Meier plotter (<http://kmplot.com/>) (23) and PROGgeneV2 (24). Two groups of patients were used for the comparison on survival rates with high and low expression levels of HCN1, HCN2, HCN3 and HCN4 gene.

All the searches were performed from December 2015 to December 2016.

Results

Expression of HCN1 in multiple types and subtypes of cancer

In general, HCN1 gene over-expressed in diverse types of cancer such as colorectal cancer, leukemia, lung cancer, melanoma, and prostate cancer whereas the mRNA expression of HCN1 was under-expressed in breast cancer and bladder cancer. In addition, HCN1 gene also over and under expressed in both lymphoma and pancreatic cancer (Figure 2).

The highest expression fold change of HCN1 in cancer and normal matched type tissue was displayed in Figure 3. HCN1 expression in brain cancer particular in glioblastoma, glioma was extremely low with the lowest fold change of -151 -fold relative to normal brain tissue. However, HCN1 expression was up-regulated in hepatocellular carcinoma and lung cancer with the fold change of 18.8 and 19.9-fold respectively.

Survival analysis of HCN1 expression using Kaplan-Meier plotter and PROGgeneV2 showed that HCN1

had significant correlation with mortality in breast cancer [hazard ratio (HR) = 7.42, $P = 0.0019$] and colorectal cancer (HR = 1.66, $P = 0.0071$) (Figure 4).

Expression of HCN2 in multiple types and subtypes of cancer

In our study, we found that HCN2 gene overexpressed in colorectal cancer, kidney cancer, lung cancer, lymphoma, melanoma, and prostate cancer whereas HCN2 expression level showed both up and down regulation in breast cancer, leukemia, pancreatic cancer, sarcoma, and kidney cancer (Figure 2).

HCN2 fold change was calculated and displayed in Figure 5. HCN2 expression was down-regulated in esophageal squamous cell carcinoma with fold change of -37.3 and -21.6 -fold relative to normal matched type tissue. In contrast, HCN2 was up-regulated in lung cancer, breast cancer, liver cancer, and thyroid cancer with 38.1, 21.4, 13.3, 10.9-fold respectively higher than normal control tissue.

To further investigate the expression of HCN2 and overall survival rate of cancer patients, we used Kaplan-Meier plotter analysis and PROGgeneV2 and found that the lower survival rates of lung cancer (HR = 2.5, $P = 0.0107$), kidney cancer (HR = 1.1, $P = 0.004$) and gastric cancer (HR = 1.33, $P = 0.0037$) had significant correlation with the expression of HCN2 (Figure 6). The current data suggested that overexpression of HCN2 may be involved in the particular process of lung cancer. This observation may make HCN2 a potential biomarker for esophageal squamous cell carcinoma, lung cancer, kidney cancer and gastric cancer, breast cancer, liver cancer, and thyroid cancer diagnosis and prognosis.

Expression of HCN3 in multiple types and subtypes of cancer

Our data showed that HCN3 gene over-expressed in breast cancer, kidney cancer, lung cancer, liver cancer, gastric cancer, ovarian cancer, bladder cancer, kidney cancer whereas HCN3 was under-expressed in prostate cancer (Figure 2).

HCN3 was under expressed in many subtypes of brain cancer such as primary tumor dermal neurofibroma, cultured plexiform neurofibroma-derived Schwann cell, pediatric tumor tissue ependymoma, pediatric tumor tissue anaplastic astrocytoma with fold change of -4.5 , -3.5 ,

Genes \ Cancer types	HCN1	HCN2	HCN3	HCN4
Breast cancer				
Colorectal cancer				
Kidney cancer				
Leukemia				
Lung cancer				
Lymphoma				
Melanoma				
Pancreatic cancer				
Postate cancer				
Sarcoma				
Liver				
Gastric				
Ovarian				
Bladder				
Kidney				
Esophageal				
Thyroid				

Figure 2 Expression of hyperpolarization-activated cyclic nucleotide-gated genes in multiple types of cancer. Expression of HCN genes in 17 types of cancers compared to normal matched type tissue controls. The color correlates with over and under expression of genes in specific cancer. Red color represents for over expression and blue color represents for under expression. The search criteria threshold was set at $P < 0.05$ with fold change > 1.5 and gene rank percentile $< 10\%$ for screening microarray datasets of cancer versus normal cases. HCN, hyperpolarization-activated cyclic nucleotide-gated.

-3.2, -3-fold respectively compared to normal matched type tissue (Figure 7). In contrast, HCN3 over-expressed in liver and lung cancer tissue with fold change of 3.9 and 3.6 respectively, relatively to normal matched type sample (Figure 7).

In addition, Kaplan-Meier plotter and PROGgeneV2 analysis showed overexpression of HCN3 in breast cancer was significantly correlated with lower survival rates

and poor prognosis value of breast cancer (HR =1.65, $P=0.0016$), kidney cancer (HR =1.17, $P=0.0049$) but higher survival rate and good prognosis value in lung cancer (HR =0.33, $P=0.0272$) and ovarian cancer (HR =0.53, $P=0.0386$) patients (Figure 8). This result may indicate HCN3 as a potential biomarker for diagnosis and prognosis of brain cancer, breast cancer, kidney cancer, lung cancer and ovarian cancer.




Figure 3 Expression of HCN1 genes in multiple subtypes of 17 cancers. Only two datasets shown over expression of HCN1 in cancer while the rest of cancer subtype had under expression of HCN1.




Figure 4 HCN1 mRNA expression and overall survival patient with breast cancer and colorectal cancer. High expression of HCN1 results in poor survival rate of patient in 3 and 5 years' period. $P < 0.05$ means statistically significant difference.

Expression of HCN4 in multiple types and subtypes of cancer

HCN4 gene was found over-expression in kidney cancer, leukemia, lung cancer, sarcoma, ovarian cancer, and thyroid cancer whereas it under expressed in breast cancer. In

addition, both over and under expression of HCN4 were found in bladder cancer, kidney cancer, and esophageal cancer (Figure 2).

HCN4 was under-expressed in stage I and II endometrial carcinoma with the fold change extremely low (-157 and




Figure 5 Expression of HCN2 genes in multiple subtypes of 17 cancers. High expression of HCN2 was recorded in multiple subtypes of cancer.




Figure 6 HCN2 mRNA expression and overall survival patient with kidney cancer, lung cancer and gastric cancer. High expression of HCN2 results in poor survival rate of patient in 3 and 5 years' period. $P < 0.05$ means statistically significant difference.




Figure 7 Expression of HCN3 genes in multiple subtypes of 17 cancers. High and low expression of HCN3 was recorded in multiple subtypes of cancer.




Figure 8 HCN3 mRNA expression and overall survival patient with breast cancer, kidney cancer, lung cancer and ovarian cancer. High expression of HCN3 results in poor survival rate of patient in 3 and 5 years' period. P<0.05 means statistically significant difference.




Figure 9 Expression of HCN4 genes in multiple subtypes of 17 cancers. High and low expression of HCN4 was recorded in multiple subtypes of cancer. HCN4 shown extremely low expression level in stage I endometrioid carcinoma and high expression in thyroid carcinoma.

-135-fold). In contrast, HCN4 was over expressed in Thyroid carcinomas, Thyroid tissues-papillary thyroid carcinoma, liver cancer, and prostate cancer with fold change of 30.4, 10, 11.2, and 7.8-fold respectively (*Figure 9*).

Kaplan-Meier plotter analysis showed that upregulation of HCN4 was highly correlated with the lower survival rates of patients with gastric cancer (HR =1.25, P=0.022), lung cancer (HR =5.37, P=0.0433) and ovarian cancer (HR =13.58, P=0.0426) but higher survival rate in patient with breast cancer (HR =0.8, P=0.00016) (*Figure 10*). From these results, HCN4 can be considered as the potential marker in breast cancer, gastric cancer, lung cancer and ovarian cancer diagnosis, thyroid carcinomas.

Discussion

In this study, we showed that HCN family members (HCN1, HCN2, HCN3, HCN4) overexpressed in numerous cancerous tissue relative to normal matched tissue. The increased expression of these four genes in multiple types and subtypes of cancer was also significantly correlated with low and high survival rates of cancer patients. This correlation suggests that HCN genes might play a key role in cancer particularly in brain cancer, lung cancer, liver cancer, esophageal cancer, thyroid cancer, ovarian cancer which had notably high fold change compared to normal matched type tissue. However, further study is required to confirm the

mechanism of how HCN genes play a role in cancer.

In neuropathic pain, lacking of HCN1 gene expression by genetic deletion showed mitigation in neuronal damage (25). Another research showed that HCN1 deficiency caused epilepsy, ataxia and learning compromise (7). In a recent study, HCN1 showed under-expression with fold change of 0.65 in breast cancer cells after Maitake D-Fraction treatment (26). Single nucleotide polymorphism of HCN1 was found association with shorter survival of breast cancer patient (27). Moreover, inhibiting of HCN channel functions in embryonic stem cells by ZD7288, a HCN channels blocker, and cesium revealed that cell proliferation was decreased under the effects of these two drugs (28). HCN3 gene was also implied as the potential target for tumor suppression (28). In our findings, HCN3 also showed overexpression in multiple types of cancers such as breast cancer, and liver cancer. Therefore, we speculate that HCN3 is likely to be a candidate to study cancer cell proliferation and cancer cell cycle.

The HCN gene is commonly located in ventricular myocytes and neuron cells. Previous studies on the roles of the HCN channels were primarily focused on neurological diseases such as epilepsies and neuropathic pain disorders and cardiac related diseases (7,29,30). HCN channel functions are largely unknown in cancer. HCN channels (HCN1-4) have been known to allow the flow of Na⁺ and K⁺ ions (1:4 ration) inward and outward of the cell, which




Figure 10 HCN4 mRNA expression and overall survival patient with breast cancer, gastric cancer, lung cancer and ovarian cancer. High expression of HCN4 dramatically declined the survival rate of patient in 3 and 5 years' period. $P < 0.05$ means statistically significant difference.

creates a hyperpolarization activated current named I_h . This current was showed to participate in regulating the heart rate and the firing of neurons. Moreover, HCN channels also play a role in the determination of resting membrane potential, dendritic integration, synaptic transmission and learning (7). HCN2 roles in inflammatory and neuropathic pain have been uncovered recently (31). Intriguingly, apart from the permeability of Na^+ and K^+ inward cell, HCN2 and HCN4 also allow Ca^{2+} ion into the cell (32). This happened due to the dephosphorylation of Thr549 within the regulatory region of HCN2; and calcium ion influx causes cell apoptosis due to cytotoxicity (33). cAMP was acknowledged to modulate HCN2 in gating activity (34,35). Moreover, in non-small cell lung carcinomas, HCN2 has also been triggered by PKC inhibitors such as staurosporine (STS) or PKC412 and under expression of HCN2 can prevent cell apoptosis (36). As a consequence, if HCN2

is mutated or overexpressed in cancer cells, it can lead to cancer cell not going through apoptosis. Thus, HCN2 expression is crucial and likely to be a potential target for cancer treatment via inhibiting of HCN2 expression.

The current study is the pioneer meta-analysis research about HCN gene expression in multiple types and subtypes of cancer. HCN1-4 could have potency as biomarker for cancer disease diagnosis and prognosis. Further study on HCN genes and specific types of cancer as suggested in the present study may help to reveal the underlying molecular mechanism of these genes in cancer.

Acknowledgements

Funding: This project is supported by National Science Council of Yuan (NSC 104-2320-B-034-003; NSC 105-2320-B-034-001 to YC Lin).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015;136:E359-86.
2. Zugazagoitia J, Guedes C, Ponce S, et al. Current Challenges in Cancer Treatment. *Clin Ther* 2016;38:1551-66.
3. Kaupp UB, Seifert R. Molecular diversity of pacemaker ion channels. *Annu Rev Physiol* 2001;63:235-57.
4. Notomi T, Shigemoto R. Immunohistochemical localization of Ih channel subunits, HCN1-4, in the rat brain. *J Comp Neurol* 2004;471:241-76.
5. Bender RA, Baram TZ. Hyperpolarization activated cyclic-nucleotide gated (HCN) channels in developing neuronal networks. *Prog Neurobiol* 2008;86:129-40.
6. Larsson HP. How is the heart rate regulated in the sinoatrial node? Another piece to the puzzle. *J Gen Physiol* 2010;136:237-41.
7. Postea O, Biel M. Exploring HCN channels as novel drug targets. *Nat Rev Drug Discov* 2011;10:903-14.
8. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. *Neoplasia* 2007;9:166-80.
9. Rhodes DR, Yu J, Shanker K, et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. *Neoplasia* 2004;6:1-6.
10. MacDonald JW, Ghosh D. COPA--cancer outlier profile analysis. *Bioinformatics* 2006;22:2950-1.
11. Wilson BJ, Giguère V. Identification of novel pathway partners of p68 and p72 RNA helicases through Oncomine meta-analysis. *BMC Genomics* 2007;8:419.
12. Blonska M, Lin X. NF- κ B signaling pathways regulated by CARMA family of scaffold proteins. *Cell Res* 2011;21:55-70.
13. McDaniel AS, Hovelson D, Cani A, et al. 187 Targeted genomic profiling of penile squamous cell carcinoma using the Oncomine cancer research panel. *Eur J Cancer* 2014;50:61.
14. Wang CY, Lai MD, Phan NN, et al. Meta-Analysis of Public Microarray Datasets Reveals Voltage-Gated Calcium Gene Signatures in Clinical Cancer Patients. *PLoS One* 2015;10:e0125766.
15. Phan NN, Wang CY, Chen CF, et al. Voltage-gated calcium channels: Novel targets for cancer therapy. *Oncol Lett* 2017;14:2059-74.
16. Wang CY, Shahi P, Huang JT, et al. Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients. *Mol Clin Oncol* 2017;6:7-18.
17. Coppola G. editor. *The OMICs: Applications in Neuroscience*. Oxford: Oxford University Press, 2013.
18. Cohen T, Sundaresh S, Levine F. Antipsychotics activate the TGF β pathway effector SMAD3. *Mol Psychiatry* 2013;18:347-57.
19. Kupersmidt I, Su QJ, Grewal A, et al. Ontology-based meta-analysis of global collections of high-throughput public data. *PLoS One* 2010;5(9).
20. Ewald JA, Downs TM, Cetnar JP, et al. Expression microarray meta-analysis identifies genes associated with Ras/MAPK and related pathways in progression of muscle-invasive bladder transition cell carcinoma. *PLoS One* 2013;8:e55414.
21. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med* 2009;6:e1000097.
22. Rhodes DR, Chinnaiyan AM. Integrative analysis of the cancer transcriptome. *Nat Genet* 2005;37 Suppl:S31-7.
23. Györfy B, Surowiak P, Budczies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. *PLoS One* 2013;8:e82241.
24. Goswami CP, Nakshatri H. PROGgeneV2: enhancements on the existing database. *BMC Cancer* 2014;14:970.
25. Momin A, Cadiou H, Mason A, et al. Role of the hyperpolarization-activated current Ih in somatosensory neurons. *J Physiol* 2008;586:5911-29.
26. Alonso EN, Orozco M, Eloy Nieto A, et al. Genes related to suppression of malignant phenotype induced by Maitake D-Fraction in breast cancer cells. *J Med Food* 2013;16:602-17.
27. Kuo SH, Yang SY, You SL, et al. Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer. *Oncotarget* 2017;8:20925-38.
28. Lau YT, Wong CK, Luo J, et al. Effects of hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blockers on the proliferation and cell cycle progression of embryonic stem cells. *Pflugers Arch* 2011;461:191-202.

29. Poolos NP. The Yin and Yang of the H-Channel and Its Role in Epilepsy. *Epilepsy Curr* 2004;4:3-6.
30. Ueda K, Nakamura K, Hayashi T, et al. Functional characterization of a trafficking-defective HCN4 mutation, D553N, associated with cardiac arrhythmia. *J Biol Chem* 2004;279:27194-8.
31. Emery EC, Young GT, Berrococo EM, et al. HCN2 ion channels play a central role in inflammatory and neuropathic pain. *Science* 2011;333:1462-6.
32. Yu X, Duan KL, Shang CF, et al. Calcium influx through hyperpolarization-activated cation channels (Ih channels) contributes to activity-evoked neuronal secretion. *Proc Natl Acad Sci U S A* 2004;101:1051-6.
33. Norberg E, Karlsson M, Korenovska O, et al. Critical role for hyperpolarization-activated cyclic nucleotide-gated channel 2 in the AIF-mediated apoptosis. *EMBO J* 2010;29:3869-78.
34. Ulens C, Tytgat J. Gi- and Gs-coupled receptors up-regulate the cAMP cascade to modulate HCN2, but not HCN1 pacemaker channels. *Pflugers Arch* 2001;442:928-42.
35. Wainger BJ, DeGennaro M, Santoro B, et al. Molecular mechanism of cAMP modulation of HCN pacemaker channels. *Nature* 2001;411:805-10.
36. Norberg E, Gogvadze V, Ott M, et al. An increase in intracellular Ca²⁺ is required for the activation of mitochondrial calpain to release AIF during cell death. *Cell Death Differ* 2008;15:1857-64.

Cite this article as: Phan NN, Huynh TT, Lin YC. Hyperpolarization-activated cyclic nucleotide-gated gene signatures and poor clinical outcome of cancer patient. *Transl Cancer Res* 2017. doi: 10.21037/tcr.2017.07.22

Table S1 HCN1 expression in multiple types of cancer from NextBio Research database

Cancer type	Subtype	P value	Fold change (cancer/normal)	N	References
Brain cancer	Anaplastic astrocytomas WHO grade III	5.80×10 ⁻⁵	-11.0	5	(37)
	Astrocytoma grade III	0.0162	4.7	3	(38)
	Brain from newly diagnosed WHO grade 4 glioblastoma patients	3.00×10 ⁻²⁰	-151.0	40	(39)
	Brain from oligodendroglioma	5.00×10 ⁻⁸	-7.8	50	(40)
	Brain glioma stem cells	0.0171	-20.6	N/A	(41)
	Brain tissue—astrocytomas	2.70×10 ⁻³³	-9.8	148	(42)
	Brain tissue—tumors with mixed histology	3.10×10 ⁻⁵	-8.8	11	(42)
	Brain tumor samples of WHO grade 2 diffusely infiltrative astrocytoma	9.40×10 ⁻⁵	-12.1	5	(43)
	Brain tumor samples of WHO grade 2 ependymoma	0.0274	-7.7	4	(43)
	Brain tumor samples of WHO grade 2 oligodendroglioma	0.0165	-6.5	5	(43)
	Brain tumor tissues from adult patients with high grade glioma	0.0028	-34.6	7	(43)
	Brain tumor tissues from patients with atypical teratoid-rhabdoid tumor	0.0051	-35.4	17	(43)
	Brain tumor tissues from patients with group 3 medulloblastoma	0.0173	-6.0	4	(43)
	Brain tumor tissues from patients with group 4 medulloblastoma	0.0017	-16.5	7	(43)
	Brain tumor tissues from patients with posterior fossa group B ependymoma	0.0163	-5.1	26	(43)
	Brain tumor tissues from patients with sonic hedgehog medulloblastoma	0.0017	-27.0	8	(43)
	Brain tumor tissues from patients with supratentorial ependymoma	0.018	-47.3	9	(43)
	Brain tumor tissues from pediatric patients with high grade glioma	0.0128	-39.2	14	(43)
	Classic medulloblastomas	0.0114	-1.8	N/A	(44)
	Giant cell glioblastoma	0.0007	-36.4	5	(45)
	Glioblastoma	4.60×10 ⁻⁶	-43.2	1	(45)
	Glioblastoma multiforme grade IV	6.00×10 ⁻¹⁰	-4.4	6	(46)
	Glioblastoma multiforme solid tumor	0.0016	-1.7	19	(47)
	Glioblastoma multiforme tumors in pediatric cases	0.0041	-16.1	25	(48)
	Glioblastoma multiforme tumors of classical subtype	2.50×10 ⁻¹⁴	-30.7	N/A	(48)
	Glioblastoma multiforme tumors of G-CIMP (-) subtype	9.80×10 ⁻¹²	-25.1	N/A	(48)
	Glioblastoma multiforme tumors of G-CIMP (+) subtype	3.80×10 ⁻¹⁶	-25.2	N/A	(48)
	Glioblastoma multiforme tumors of mesenchymal subtype	5.60×10 ⁻¹³	-32.6	N/A	(48)
	Glioblastoma multiforme tumors of neural subtype	4.00×10 ⁻¹⁶	-12.7	N/A	(48)
	Glioblastoma multiforme tumors of patients surviving less than 3 months	7.00×10 ⁻¹⁸	-28.9	N/A	(48)
	Glioblastoma multiforme tumors of patients surviving longer than 36 months	7.60×10 ⁻¹⁷	-25.8	N/A	(48)
	Glioblastoma multiforme tumors of proneural and G-CIMP (-) subtypes	2.60×10 ⁻¹⁵	-22.3	N/A	(48)
	Glioblastoma multiforme tumors of proneural and G-CIMP (+) subtypes	2.10×10 ⁻¹⁶	-26.8	N/A	(48)
	Glioblastoma multiforme tumors of proneural subtype	2.90×10 ⁻¹⁵	-21.0	N/A	(48)
	Glioblastomas brain tumors	0.0115	-33.2	N/A	(49)
	Pediatric brain tissue—glioblastoma tumor	7.40×10 ⁻¹⁴	-69.0	12	(50)
	Pediatric brain tissue—glioblastoma tumor	9.80×10 ⁻⁷	-68.5	12	(50)
	Pediatric brain tissue—glioblastoma tumor	6.30×10 ⁻¹³	-73.3	12	(50)
	Pediatric brain tissue—glioblastoma tumor	5.10×10 ⁻⁶	-70.5	12	(50)
	Pediatric brain tissue—glioblastoma tumor	4.00×10 ⁻¹²	-63.6	12	(50)
	Pediatric cerebellum from medulloblastoma patients (aged 114–155 months)	0.0437	-4.2	7	(50)
	Pediatric cerebellum from medulloblastoma patients (aged 27–51 months)	0.0028	-6.7	8	(51)
	Pediatric cerebellum from medulloblastoma patients	1.70×10 ⁻⁵	-6.7	19	(51)
	Pilocytic astrocytomas from cerebellums	5.20×10 ⁻²¹	-26.3	35	(52)
	Primary melanoma—superficial spreading melanoma	0.001	2.3	46	(53)
	Primary neuroblastoma with 11q deletion	0.0457	-2.0	8	(54)
	Primary tumor dermal neurofibromas	0.0104	-17.6	13	(55)
	Primary tumor malignant peripheral nerve sheath tumors	0.01	-11.4	13	(55)
	Primary tumor plexiform neurofibroma	0.0033	2.9	13	(56)
	Primary tumor plexiform neurofibromas	0.0113	-24.4	6	(55)
Diffusely infiltrating astrocytic gliomas WHO grade II	0.0132	-7.6	5	(43)	
Oligoastrocytoma	3.60×10 ⁻⁶	-47.0	2	(45)	
Kidney cancer	Adrenal tissue from pheochromocytoma patients with HIF2A mutation	0.0012	2.5	1	GSE50442
	Adrenal tissue from pheochromocytoma patients with PHD2 mutation	8.40×10 ⁻⁵	-4.2	1	GSE50442
Breast cancer	Breast cancer tumors from TCGA patients	1.20×10 ⁻¹⁶	-3.0	1,018	TCGA
Colorectal cancer	Colon carcinoma LS174T cells (undifferentiated)	3.70×10 ⁻⁶	9.6	3	(45)
Skin cancer	Skin tissue—primary Merkel cell carcinoma non-viral origin	0.0274	3.0	7	(57)
Stomach cancer	Stomach cancer with diffuse morphology stage IIIA	0.0026	1.5	6	(58)
Liver cancer	Hepatocellular carcinoma etiology alpha-1 antitrypsin deficiency	0.0065	18.8	N/A	(59)
	Intrahepatic cholangiocarcinomas of inflammation subtype	0.0174	-1.7	57	(60)
	Intrahepatic cholangiocarcinomas of proliferation subtype	0.0063	-2.0	92	(60)
Lymphoma	Large granular lymphocyte leukemia cells wild type STAT3	0.0315	4.3	1	(61)
Lung cancer	Lung adenocarcinomas from TCGA patients	9.00×10 ⁻⁸	7.3	454	TCGA
	Lung FFPE—tumor	1.10×10 ⁻⁵	19.9	4	(62)
Melanoma	Melanoma skin biopsies—primary melanoma	0.0004	2.0	46	(53)
Pancreatic cancer	Pancreatic ductal adenocarcinoma tissues	2.80×10 ⁻⁶	-2.6	6	(63)
Thyroid cancer	Papillary thyroid carcinomas with BRAF mutation	3.10×10 ⁻⁷	-4.2	14	GSE54958
	Papillary thyroid carcinomas without BRAF mutation	5.20×10 ⁻⁷	-4.0	11	GSE54958

FFPE, formalin-fixed paraffin-embedded.

Table S2 HCN1 expression in multiple types of cancer from Oncomine database

Cancer	Subtype	N (case)	Expression	P value (cancer/normal)	t-test (cancer/normal)	Fold (cancer/normal)	Gene ranking (%)	Database
Brain and CNS cancer	Anaplastic oligoastrocytoma	54	↓	2.25×10 ⁻⁴	-5.732	-4.034	417 (in top 3%)	Cancer Res 2005/10/01 (64)
	Oligodendroglioma	54	↓	0.001	-4.643	-3.418	746 (in top 6%)	Cancer Res 2005/10/01 (64)
	Glioblastoma	54	↓	6.71×10 ⁻⁶	-6.333	-4.106	1,116 (in top 8%)	Cancer Res 2005/10/01 (64)
	Anaplastic oligodendroglioma	54	↓	0.005	-5.540	-5.176	1,437 (in top 10%)	Cancer Res 2005/10/01 (64)
	Glioblastoma	NA	↓	9.08×10 ⁻⁶	-20.032	-18.892	675 (in top 4%)	J Clin Oncol 2008/06/20 (65)
	Anaplastic oligoastrocytoma	180	↓	2.12×10 ⁻⁶	-5.321	-5.462	1,592 (in top 9%)	Cancer Cell 2006/04/01 (40)
	Glioblastoma	180	↓	8.01×10 ⁻¹⁴	-9.613	-20.247	1,615 (in top 9%)	Cancer Cell 2006/04/01 (40)
Breast cancer	Invasive ductal and lobular carcinoma	593	↓	2.65×10 ⁻⁴	-8.273	-2.809	957 (in top 5%)	TCGA 2011/09/02
	Male breast carcinoma	593	↓	0.003	-5.409	-2.113	2,024 (in top 10%)	TCGA 2011/09/02
	Invasive breast carcinoma	158	↓	0.002	-7.245	-2.780	1,530 (in top 9%)	Breast Cancer Res Treat 2011/03/04 (66)
Colorectal cancer	Rectal mucinous adenocarcinoma	237	↑	4.13×10 ⁻⁷	8.326	3.800	225 (in top 2%)	TCGA Colorectal 2011/09/08
Lymphoma	Marginal zone B-cell lymphoma	27	↑	0.007	3.171	1.576	388 (in top 3%)	J Invest Dermatol 2003/05/01 (67)
	Unspecified peripheral T-cell lymphoma	60	↓	5.58×10 ⁻¹³	-9.897	-1.584	249 (in top 2%)	J Clin Invest 2007/03/01 (68)
	Angioimmunoblastic T-cell lymphoma	60	↓	1.39×10 ⁻⁴	-7.676	-1.967	1,817 (in top 10%)	J Clin Invest 2007/03/01 (68)
Melanoma	Cutaneous melanoma	87	↑	0.007	2.763	2.479	1,548 (in top 8%)	BMC Med Genomics 2008/04/28 (69)

Table S3 HCN2 expression in multiple types of cancer from NextBio Research database

Cancer subtype	P value	Fold change	N	References
Lung FFPE	0.0012	38.1	4	(62)
Breast cancer tumors from TCGA patients	4.00×10 ⁻⁵⁸	21.4	1,018	TCGA
Liver hepatocellular carcinomas from TCGA patients	2.00×10 ⁻¹⁷	13.3	165	TCGA
Thyroid carcinomas from TCGA patients	1.20×10 ⁻¹³	10.9	500	TCGA
Lung adenocarcinomas from TCGA patients	8.20×10 ⁻¹⁹	6.9	454	TCGA
Hepatocellular carcinomas from hepatitis B virus-positive patients	3.40×10 ⁻⁶	5	10	(70)
B cells CD19+ from peripheral blood—chronic lymphocytic leukemia with mutated IGVH	0.0002	4.6	4	GSE70830
Actinic keratosis cells	7.80×10 ⁻⁷	3.3	5	GSE42677
Prostate adenocarcinomas from TCGA patients	6.70×10 ⁻¹²	3.3	259	TCGA
Seminoma cells	0.0006	3.1	23	(71)
Lung squamous cell carcinomas from TCGA patients	2.80×10 ⁻⁹	2.8	482	TCGA
Thyroid tissues—papillary thyroid carcinoma patients	0.006	2.8	18	(72)
Lung adenocarcinoma primary tumors	0.0044	2.8	6	(73)
Bladder cancer tumors from TCGA patients	0.0025	2.6	223	TCGA
Livers of hepatocellular carcinoma patients	0.0004	2.5	12	GSE56545
Oncocytoma	1.40×10 ⁻⁹	2.2	7	(74)
iPS cells derived from bone marrow mononuclear cells of CML patient	0.0438	2.1	1	(75)
Pancreatic neuroendocrine tumors	0.0024	2	6	(76)
Chromophobe renal tumor	0.005	2	6	(74)
Renal tissue—ChRCC	9.70×10 ⁻⁵	2	10	(77)
Primary melanoma (before treatment)	0.0253	2	31	(77)
Primary melanoma culture	0.01	1.9	2	(78)
Lymphoma cells of lymph nodes of tcr-cHL	0.0011	1.7	4	(79)
Adrenal tissue from pheochromocytoma patients with HIF2A mutation	0.0054	1.6	1	GSE50442
Nodular lymphocyte predominant Hodgkin lymphoma	0.0422	1.6	5	(80)
Mesenchymal stem cells 7–9 passages—large granular lymphocyte leukemia	0.0332	1.6	2	(81)
Prostate cancer stage T2	0.0051	1.5	3	(82)
Breast cancer Luminal A subtype	0.0005	1.5	39	(83)
Familial pancreatic intraepithelial neoplasias	0.0439	-1.6	13	(84)
Metastatic breast tumor	0.0298	-1.6	5	(85)
Pancreatic intraepithelial neoplasias of family C	0.0363	-1.6	2	(84)
Intestinal cancer stage IB	0.0055	-1.7	10	(58)
High-stage neuroblastoma	0.0076	-1.7	12	(86)
Infiltrating ductal mammary carcinoma	1.10×10 ⁻²⁷	-1.7	68	(87)
Pancreatic intraepithelial neoplasias of family X	0.0349	-1.7	7	(84)
Esophageal squamous cancer cell line	0.0021	-1.7	20	(88)
Brain tissue—glioblastoma tumors	1.40×10 ⁻⁵	-1.8	48	(89)
Glioblastomas brain tumors	1.50×10 ⁻⁷	-1.9	34	(49)
Low-stage neuroblastoma	0.0046	-1.9	6	(86)
Brain tumor tissues from patients with sonic hedgehog medulloblastoma	0.0034	-1.9	8	(90)
Brain tumor tissues from patients with posterior fossa group B ependymoma	1.20×10 ⁻⁹	-2.1	26	(90)
Brain tumor tissues from patients with posterior fossa group A ependymoma	7.00×10 ⁻¹⁰	-2.2	29	(90)
Molecular profiling of PBMC from T-cell LGL	0.001	-2.2	30	(91)
Pilocytic astrocytoma tumor	0.0319	-2.5	6	GSE12657
Brain tumor tissues from patients with atypical teratoid-rhabdoid tumor	1.20×10 ⁻⁹	-2.5	17	(90)
Brain tumor tissues from adult patients with high grade glioma	7.80×10 ⁻⁶	-2.6	7	(90)
Glioblastoma tumor	0.0138	-2.9	7	GSE12657
Hepatocellular carcinoma early stage tissue	0.0011	-3	13	(92)
Intrahepatic cholangiocarcinomas of proliferation subtype	0.0441	-3.4	92	(60)
Plasma cells from multiple myeloma patients	0.0009	-4.2	12	GSE9656
ESCC	0.001	-5.8	4	(93)
ESCC	5.90×10 ⁻¹²	-21.6	3	(93)
ESCC tumor	5.70×10 ⁻²³	-37.3	3	(94)

FFPE, formalin-fixed paraffin-embedded; ChRCC, chromophobe renal cell carcinoma; ESCC, esophageal squamous cell carcinoma.

Table S4 HCN2 expression in multiple types of cancer from Oncomine database

Cancer	Subtype	N (case)	Expression	P value (cancer/normal)	t-test (cancer/normal)	Fold (cancer/normal)	Gene ranking (%)	Database
Brain and CNS cancer	Pilocytic astrocytoma	15	↓	9.16×10 ⁻⁵	-6.322	-8.917	35 (in top 1%)	Cancer Res 2002/04/01 (95)
	Glioblastoma	42	↓	3.80×10 ⁻⁴	-5.350	-2.314	423 (in top 5%)	Oncogene 2003/07/31 (96)
	Anaplastic oligoastrocytoma	33	↓	0.004	-3.452	-1.634	1,053 (in top 6%)	Cancer Res 2006/12/15 (97)
Colorectal cancer	Rectal adenocarcinoma	105	↑	4.86×10 ⁻⁵	7.292	1.703	500 (in top 3%)	Genome Biol 2007/07/05 (98)
	Rectosigmoid adenocarcinoma	105	↑	6.94×10 ⁻⁵	5.439	1.653	1,158 (in top 6%)	Genome Biol 2007/07/05 (98)
	Colon mucinous adenocarcinoma	105	↑	6.08×10 ⁻⁵	5.281	1.627	1,817 (in top 10%)	Genome Biol 2007/07/05 (98)
Kidney cancer	Chromophobe renal cell carcinoma	92	↑	4.49×10 ⁻¹⁷	32.987	3.932	55 (in top 1%)	Clin Cancer Res 2005/08/15 (99)
	Renal oncocytoma	92	↑	2.49×10 ⁻²¹	29.783	4.067	81 (in top 1%)	Clin Cancer Res 2005/08/15 (99)
	Chromophobe renal cell carcinoma	67	↑	4.54×10 ⁻⁴	5.524	13.081	384 (in top 2%)	BMC Cancer 2009/05/18 (100)
	Clear cell sarcoma of the kidney	35	↑	0.002	3.783	2.287	703 (in top 6%)	Clin Cancer Res 2005/11/15 (101)
	Clear cell renal cell carcinoma	67	↓	0.002	-3.053	-1.743	1,314 (in top 7%)	BMC Cancer 2009/05/18 (100)
	Papillary renal cell carcinoma	67	↓	0.008	-2.592	-1.901	1,862 (in top 10%)	BMC Cancer 2009/05/18 (100)
Leukemia	Chronic lymphocytic leukemia	336	↑	2.22×10 ⁻⁵	4.424	3.524	593 (in top 7%)	Nat Genet 2005/04/01 (102)
	Acute myeloid leukemia	293	↓	6.89×10 ⁻⁴	-4.515	-1.676	313 (in top 3%)	N Engl J Med 2004/04/15 (103)
	T-cell prolymphocytic leukemia	14	↓	0.003	-3.494	-3.069	726 (in top 6%)	Leukemia 2007/10/01 (104)
Lung cancer	Lung carcinoid	203	↑	8.10×10 ⁻⁷	6.593	6.774	120 (in top 2%)	Proc Natl Acad Sci U S A (105)
Lymphoma	Mantle cell lymphoma	336	↑	2.89×10 ⁻⁶	6.249	5.514	182 (in top 3%)	Nat Genet 2005/04/01 (102)
Melanoma	Cutaneous melanoma	70	↑	2.94×10 ⁻⁸	9.804	7.039	253 (in top 3%)	Clin Cancer Res 2005/10/15 (106)
Pancreatic cancer	Pancreatic ductal adenocarcinoma epithelia	25	↑	0.002	3.254	1.649	110 (in top 1%)	Neoplasia 2004/09/01 (107)
	Pancreatic ductal adenocarcinoma	38	↓	0.001	-4.137	-4.343	648 (in top 5%)	Oncogene 2005/10/06 (108)
Sarcoma	Clear cell sarcoma of the kidney	35	↑	0.002	3.783	2.287	703 (in top 6%)	Clin Cancer Res 2005/11/15 (101)
	Synovial sarcoma	54	↓	0.001	-3.655	-2.616	541 (in top 5%)	Cancer Res 2005/07/01 (109)
	Leiomyosarcoma	54	↓	0.004	-2.985	-2.238	957 (in top 8%)	Cancer Res 2005/07/01 (109)

Table S5 HCN3 expression in multiple types of cancer from NextBio Research database

Cancer types	Subtypes	P value	Fold change	N (sample)	References
Brain	Diffusely infiltrating astrocytic gliomas WHO grade II	0.0022	-1.7	5	(43)
	Pediatric tumor tissue pilocytic astrocytoma	0.0021	-1.8	15	(110)
	Pediatric tumor tissue ependymoma	0.0009	-1.9	14	(110)
	Glioblastoma multiforme tumors of neural subtype	3.10×10^{-9}	-2.2	N/A	(48)
	Pediatric tumor tissue diffuse astrocytoma	0.0149	-2.4	3	(110)
	Primary tumor dermal neurofibromas	0.0009	-2.5	13	(55)
	Pediatric tumor tissue glioblastoma	0.0014	-2.5	5	(110)
	Primary tumor malignant peripheral nerve sheath tumors	0.0005	-2.6	13	(55)
	Brain glioma stem cells	0.0011	-2.8	N/A	(41)
	Cultured NF1-derived primary benign neurofibroma Schwann cells	1.20×10^{-7}	-2.8	11	(56)
	Pediatric tumor tissue anaplastic astrocytoma	0.0029	-3.0	2	(110)
	Pediatric tumor tissue ependymoma	0.0006	-3.2	14	(110)
	Cultured plexiform neurofibroma-derived Schwann cell	1.10×10^{-7}	-3.5	11	(56)
	Primary tumor dermal neurofibroma	6.50×10^{-9}	-4.2	13	(56)
	Primary tumor plexiform neurofibroma	6.50×10^{-7}	-4.5	13	(56)
	Primary tumor malignant peripheral nerve sheath tumors	0.0005	-2.6	13	(55)
	Brain glioma stem cells	0.0011	-2.8	N/A	(41)
	Cultured NF1-derived primary benign neurofibroma Schwann cells	1.20×10^{-7}	-2.8	11	(56)
	Pediatric tumor tissue anaplastic astrocytoma	0.0029	-3.0	2	(110)
	Pediatric tumor tissue ependymoma	0.0006	-3.2	14	(110)
Cultured plexiform neurofibroma-derived Schwann cell	1.10×10^{-7}	-3.5	11	(56)	
Primary tumor dermal neurofibroma	6.50×10^{-9}	-4.2	13	(56)	
Primary tumor plexiform neurofibroma	6.50×10^{-7}	-4.5	13	(56)	
Breast	Primary breast tumor lobular carcinoma	0.0077	1.9	5	(111)
	Whole blood from patients with breast cancer	0.0132	1.7	11	(112)
	Whole blood from patients with breast cancer	0.0136	2.3	1	(112)
Leukemia	B lymphocytes (CD19+)—chronic lymphocytic leukemia	0.0004	2.2	47	GSE66117
Breast and lymphoma	Whole blood from patients with breast cancer and lymphoma	0.0302	1.6	2	(112)
Breast and intestinal	Whole blood from patients with breast and intestinal cancer	0.0367	1.9	1	(112)
Breast and gastric	Whole blood from patients with breast and gastric cancer	0.0345	1.9	1	(112)
Bladder	Primary resected bladder tumor	3.20×10^{-6}	1.9	165	(113)
	Bladder cancer tumors from TCGA patients	4.50×10^{-8}	2.9	223	TCGA
	Bladder cancer non-muscle invasive T1N0M0	0.0017	1.8	18	(114)
Colorectal	Normal epithelium from colorectal cancer patient	0.0011	2.6	8	(115)
Colon and ovarian	Whole blood from patients with colon and ovarian cancer	0.0039	1.8	5	(112)
Colon and lung	Whole blood from patients with colon and lung cancer	0.022	-2.1	1	(112)
Gastric	Gastric tumors biopsies	7.40×10^{-6}	-2.6	40	GSE33651
	Gastric cancer tissue	0.0089	1.5	8	(116)
Kidney	Renal tissue—pRCC1	1.90×10^{-11}	1.5	22	(77)
	Benign pheochromocytomas of adrenal glands SDHD mutant	0.0006	1.6	N/A	(117)
Liver	Hepatocellular carcinomas	3.60×10^{-5}	2.1	8	(118)
	Intrahepatic cholangiocarcinomas of proliferation subtype	0.0222	3.4	92	(60)
	Livers of hepatocellular carcinoma patients—non-recurrent tumor	4.50×10^{-11}	3.3	12	GSE56545
	Intrahepatic cholangiocarcinomas of inflammation subtype	0.0348	2.8	57	(60)
	Livers of hepatocellular carcinoma patients—recurrent tumor	6.30×10^{-8}	3.9	9	GSE56545
	Liver metastasis of midgut cancer	0.0298	1.8	3	(119)
	Hepatocellular carcinoma advanced stage tissue	0.0001	-3.4	13	(92)
	Hepatocellular carcinoma CTNNB1 mutant	0.0013	2.5	4	(120)
Hepatocellular carcinoma early stage tissue	0.007	-1.8	13	(92)	
Lung	Lungs frozen—carcinoid tumor	0.016	1.7	3	(121)
	Lung adenocarcinomas from TCGA patients	2.30×10^{-31}	3.6	454	TCGA
	Lung small cell carcinomas	5.90×10^{-8}	2.6	22	(122)
	Lungs in RNAlater—carcinoid tumor	0.0052	1.8	3	(121)
	Lung cancer cell line—SCLC	1.90×10^{-8}	2.0	22	(123)
	Lung carcinoid tumors	6.50×10^{-13}	3.1	24	(122)
Melanoma	Melanoma skin biopsies—primary melanoma	8.90×10^{-5}	-2.7	46	(53)
	Primary melanoma—superficial spreading melanoma	0.0003	-2.5	28	(53)
	Metastatic melanoma in short term culture	0.0231	-2.3	1	(124)
Ovarian	Blood fraction of patients with epithelial ovarian cancer	8.60×10^{-5}	-1.9	48	GSE31682
Ovarian and bladder	Whole blood from patients with ovarian and bladder cancer	0.048	1.8	1	(112)
Prostate	Metastatic prostate tumor samples	0.0005	2.6	25	(125)
Sarcoma	Pleomorphic liposarcoma tissues	0.0043	1.6	8	(126)

pRCC1, type 1 papillary renal cell carcinoma.

Table S6 HCN3 expression in multiple types of cancer from Oncomine database

Cancer	Subtype	N (case)	Expression	P value (cancer/normal)	t-test (cancer/normal)	Fold (cancer/normal)	Gene ranking (%)	Database
Breast cancer	Intraductal cribriform breast adenocarcinoma	593	↑	0.005	6.153	1.646	1,856 (in top 10%)	TCGA Breast 2011/09/02
Prostate cancer	Prostate carcinoma	122	↓	6.02×10 ⁻⁵	-4.257	-1.560	1,864 (in top 10%)	Nature 2012/05/20 (127)

Table S7 HCN4 expression in multiple types and subtype of cancer from NextBio Research database

Cancer subtypes	P value	Fold change	N (sample)	References
Thyroid carcinomas from TCGA patients vs. normal thyroid tissue	9.00×10 ⁻⁵⁸	30.36033183	500	TCGA
Livers of patients with intrahepatic cholangiocarcinoma—tumor vs. surrounding non-tumorous tissue	4.10×10 ⁻⁷	11.20081464	7	(128)
Thyroid tissues—papillary thyroid carcinoma patients vs. healthy donors	5.40×10 ⁻⁹	10.02491379	18	(72)
Primary tumor of midgut cancer vs. ileum enriched for NE producing cells	0.0483	8.27	3	(119)
Primary tumor of midgut cancer vs. normal ileum	0.0492	8.26	3	(119)
Whole blood from patients with ovarian and bladder cancer vs. healthy	0.0036	5.06	1	(112)
Pediatric cerebellum—from medulloblastoma patients (aged 27–51 months) vs. normal	0.0044	4.18	8	(51)
Lungs frozen—carcinoid tumor vs. normal controls	0.0398	4.17	3	(121)
Bladder cancer tumors from TCGA patients vs. normal bladder tissue	0.0175	3.879884125	223	TCGA
Lung carcinoid tumors vs. non-tumor controls	7.50×10 ⁻¹²	3.79	24	GSE30219
Lungs in RNAlater—carcinoid tumor vs. normal controls	0.0417	3.76	3	(121)
Breast cancer tumors from TCGA patients vs. normal breast tissue	1.70×10 ⁻⁹	3.233176205	1,018	TCGA
Liver hepatocellular carcinomas from TCGA patients vs. normal liver tissue	0.0017	3.026373943	165	TCGA
Clear cell sarcoma of kidney vs. fetal kidney	0.0061	2.61	3	(101)
Molecular profiling of PBMC from T-cell LGL vs. pooled control	0.0052	1.65	30	(91)
Prostate cancer stage T2 vs. normal	0.0227	1.63	3	(82)
Esophageal biopsies—cancerous tissue vs. normal tissue GPL8300	2.60×10 ⁻⁷	1.57	15	(129)
Tubulointerstitium of tumor nephrectomy vs. normal cadaver controls GPL14663	0.0033	-1.5	11	(129)
Thyroid tumors vs. unmatched normal thyroid biopsies	0.0095	-1.52	19	(130)
Bone marrow CD34+ progenitor cells from myelodysplastic syndrome patients vs. normal	0.0496	-1.63	14	(131)
PBMC of patients with gastrointestinal or brain cancer vs. normal mammogram	1.50×10 ⁻⁷	-1.65	22	(132)
Bone marrow from acute lymphoblastic leukemia vs. thymocytes CD8+ single positive	7.00×10 ⁻⁵	-1.69	31	GSE46170
Differentiated hepatocellular carcinoma grade III–IV vs. normal liver	7.50×10 ⁻⁵	-1.85	12	GSE36411
HCC with fibrous stroma vs. normal surrounding liver tissue	0.0227	-1.89	7	(133)
Plasma cells from multiple myeloma patients vs. healthy bone marrow GPL8300	0.0168	-2.07	12	GSE9656
Bone marrow plasma cells—monogammopathy of uncertain significance vs. normal	0.0002	-2.12	44	(134)
Undifferentiated hepatocellular carcinoma grade III–IV vs. normal liver	0.0002	-2.14	8	GSE36411
Esophagus tumors vs. adjacent matched normal esophagus biopsies	0.0004	-2.28	13	(130)
Liver cholangiocarcinoma vs. normal surrounding liver tissue	0.0064	-2.54	6	(133)
Malignant pleural mesothelioma tumors vs. normal pleura	0.0173	-2.91	40	(135)
Prostate adenocarcinomas from TCGA patients vs. normal prostate tissue	8.50×10 ⁻²³	-3.691279781	259	TCGA
Gastric tissue—primary gastric tumor vs. normal tissue	0.0192	-5.50412551	3	GSE41476
Stage II endometrial carcinoma vs. normal endometrial epithelium	0.0147	-135	72	(136)
Stage I endometrial carcinoma vs. normal endometrial epithelium	0.0136	-157	72	(136)

HCC, hepatocellular carcinoma.

Table S8 HCN4 expression in multiple type and subtype of cancer from Oncomine database

Cancer type	Subtype	N (case)	Expression	P value (cancer/normal)	t-test (cancer/normal)	Fold (cancer/normal)	Gene ranking (%)	Database
Bladder cancer	Infiltrating bladder urothelial carcinoma	60	↓	2.27×10 ⁻⁵	-5.259	-1.557	1,060 (in top 9%)	Cancer Res 2004/06/01 (137)
Breast cancer	Invasive ductal breast carcinoma	63	↓	1.66×10 ⁻⁴	-4.426	-2.551	146 (in top 1%)	Proc Natl Acad Sci U S A 2005/08/02 (138)
Esophageal cancer	Barrett's esophagus	24	↓	4.81×10 ⁻⁴	-4.929	-2.899	91 (in top 1%)	Cancer Res 2005/04/ (139)
Kidney cancer	Clear cell sarcoma of the kidney	35	↑	1.26×10 ⁻⁴	5.505	3.007	338 (in top 3%)	Clin Cancer Res 2005/11/15 (101)
	Renal pelvis urothelial carcinoma	92	↓	2.99×10 ⁻²²	-29.961	-3.660	4 (in top 1%)	Clin Cancer Res 2005/08/15 (99)
	Chromophobe renal cell carcinoma	92	↓	8.32×10 ⁻⁵	-6.343	-1.552	1,068 (in top 9%)	Clin Cancer Res 2005/08/15 (99)
Prostate cancer	Prostate carcinoma	30	↑	0.005	2.788	7.887	291 (in top 2%)	Mol Carcinog 2002/01/01 (108)
Sarcoma	Clear cell sarcoma of the kidney	35	↑	1.26×10 ⁻⁴	5.505	3.007	338 (in top 3%)	Clin Cancer Res 2005/11/15 (101)

Table S9 Preferred reporting items for systematic review and meta-analysis protocols checklist (140)

Section/topic	#	Checklist item	Reported on page
Title			
Title	1	Identify the report as a systematic review, meta-analysis, or both	1
Abstract			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number	1
Introduction			
Rationale	3	Describe the rationale for the review in the context of what is already known	1
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS)	2
Methods			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number	2
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale	2
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched	
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated	2
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis)	2
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators	2
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made	2
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis	2
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means)	2
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I ²) for each meta-analysis	2
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies)	2
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified	3,4
Results			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram	4
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations	4
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12)	4
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (I) simple summary data for each intervention group; (II) effect estimates and confidence intervals, ideally with a forest plot	5-8
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency	5-8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see item 15)	5-8
Additional analysis	23	Give results of additional analyses, if done [e.g., sensitivity or subgroup analyses, meta-regression (see item 16)]	5-8
Discussion			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers)	9
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias)	10
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research	10
Funding			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review	10

References

37. Liu Z, Xie M, Yao Z, et al. Three meta-analyses define a set of commonly overexpressed genes from microarray datasets on astrocytomas. *Mol Neurobiol* 2013;47:325-36.
38. Cai Y, Zhong X, Wang Y, et al. Screening feature genes of astrocytoma using a combined method of microarray gene expression profiling and bioinformatics analysis. *Int J Clin Exp Med* 2015;8:18004.
39. Etcheverry A, Aubry M, De Tayrac M, et al. DNA methylation in glioblastoma: impact on gene expression and clinical outcome. *BMC Genomics* 2010;11:701.
40. Sun L, Hui AM, Su Q, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. *Cancer Cell* 2006;9:287-300.
41. Liu S, Yin F, Zhang J, et al. Regulatory roles of miRNA in the human neural stem cell transformation to glioma stem cells. *J Cell Biochem* 2014;115:1368-80.
42. Madhavan S, Zenklusen JC, Kotliarov Y, et al. Rembrandt: helping personalized medicine become a reality through integrative translational research. *Mol Cancer Res* 2009;7:157-67.
43. Liu Z, Yao Z, Li C, et al. Gene expression profiling in human high-grade astrocytomas. *Comp Funct Genomics* 2011;2011:245137.
44. Zhao X, Liu Z, Yu L, et al. Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. *Neuro Oncol* 2012;14:574-83.
45. Pollard SM, Yoshikawa K, Clarke ID, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. *Cell stem cell* 2009;4:568-80.
46. Tayrac Md, Etcheverry A, Aubry M, et al. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. *Genes Chromosomes Cancer* 2009;48:55-68.
47. Liang Y, Diehn M, Watson N, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. *Proc Natl Acad Sci U S A* 2005;102:5814-9.
48. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature* 2008;455:1061-8.
49. Griesinger AM, Birks DK, Donson AM, et al. Characterization of distinct immunophenotypes across pediatric brain tumor types. *J Immunol* 2013;191:4880-8.
50. Birks DK, Donson AM, Patel PR, et al. Pediatric rhabdoid tumors of kidney and brain show many differences in gene expression but share dysregulation of cell cycle and epigenetic effector genes. *Pediatr Blood Cancer* 2013;60:1095-102.
51. Valdora F, Banelli B, Stigliani S, et al. Epigenetic silencing of DKK3 in medulloblastoma. *Int J Mol Sci* 2013;14:7492-505.
52. Lambert SR, Witt H, Hovestadt V, et al. Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. *Acta Neuropathol* 2013;126:291-301.
53. Raskin L, Fullen DR, Giordano TJ, et al. Transcriptome profiling identifies HMGA2 as a biomarker of melanoma progression and prognosis. *J Invest Dermatol* 2013;133:2585-92.
54. Łastowska M, Viprey V, Santibanez-Koref M, et al. Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data. *Oncogene* 2007;26:7432-44.
55. Jessen WJ, Miller SJ, Jousma E, et al. MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. *J Clin Invest* 2013;123:340-7.
56. Miller SJ, Jessen WJ, Mehta T, et al. Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. *EMBO Mol Med* 2009;1:236-48.
57. Harms PW, Patel RM, Verhaegen ME, et al. Distinct gene expression profiles of viral-and nonviral-associated merkel cell carcinoma revealed by transcriptome analysis. *J Invest Dermatol* 2013;133:936-45.
58. Chen X, Leung SY, Yuen ST, et al. Variation in gene expression patterns in human gastric cancers. *Mol Biol Cell* 2003;14:3208-15.
59. Neumann O, Kesselmeier M, Geffers R, et al. Methylome analysis and integrative profiling of human HCCs identify novel protumorigenic factors. *Hepatology* 2012;56:1817-27.
60. Sia D, Hoshida Y, Villanueva A, et al. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes. *Gastroenterology* 2013;144:829-40.
61. Jerez A, Clemente MJ, Makishima H, et al. STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. *Blood* 2012;120:3048-57.
62. April C, Klotzle B, Royce T, et al. Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. *PLoS One* 2009;4:e8162.
63. Frampton AE, Castellano L, Colombo T, et al.

- MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression. *Gastroenterology* 2014;146:268-77.e18.
64. Bredel M, Bredel C, Juric D, et al. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. *Cancer Res* 2005;65:8679-89.
 65. Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. *J Clin Oncol* 2008;26:3015-24.
 66. Glück S, Ross JS, Royce M, et al. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine±trastuzumab. *Breast Cancer Res Treat* 2012;132:781-91.
 67. Storz MN, van de Rijn M, Kim YH, et al. Gene expression profiles of cutaneous B cell lymphoma. *J Invest Dermatol* 2003;120:865-70.
 68. Piccaluga PP, Agostinelli C, Califano A, et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. *J Clin Invest* 2007;117:823.
 69. Riker AI, Enkemann SA, Fodstad O, et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. *BMC Med Genomics* 2008;1:13.
 70. Huang Q, Lin B, Liu H, et al. RNA-Seq analyses generate comprehensive transcriptomic landscape and reveal complex transcript patterns in hepatocellular carcinoma. *PLoS One* 2011;6:e26168.
 71. Sperger JM, Chen X, Draper JS, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. *Proc Natl Acad Sci U S A* 2003;100:13350-5.
 72. Costa V, Esposito R, Ziviello C, et al. New somatic mutations and WNK1-B4GALNT3 gene fusion in papillary thyroid carcinoma. *Oncotarget* 2015;6:11242.
 73. Li L, Wei Y, To C, et al. Integrated omic analysis of lung cancer reveals metabolism proteome signatures with prognostic impact. *Nat Commun* 2014;5:5469.
 74. Kort EJ, Farber L, Tretiakova M, et al. The E2F3-Oncomir-1 axis is activated in Wilms' tumor. *Cancer Res* 2008;68:4034-8.
 75. Hu K, Yu J, Suknuntha K, et al. Efficient generation of transgene-free induced pluripotent stem cells from normal and neoplastic bone marrow and cord blood mononuclear cells. *Blood* 2011;117:e109-19.
 76. Park M, Kim M, Hwang D, et al. Characterization of gene expression and activated signaling pathways in solid-pseudopapillary neoplasm of pancreas. *Mod Pathol* 2014;27:580-93.
 77. Ooi A, Wong JC, Petillo D, et al. An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. *Cancer Cell* 2011;20:511-23.
 78. Hoek K, Rimm DL, Williams KR, et al. Expression profiling reveals novel pathways in the transformation of melanocytes to melanomas. *Cancer Res* 2004;64:5270-82.
 79. Eckerle S, Brune V, Döring C, et al. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma. *Leukemia* 2009;23:2129-38.
 80. Brune V, Tiacchi E, Pfeil I, et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. *J Exp Med* 2008;205:2251-68.
 81. Mailloux AW, Zhang L, Moscinski L, et al. Fibrosis and Subsequent Cytopenias Are Associated with Basic Fibroblast Growth Factor-Deficient Pluripotent Mesenchymal Stromal Cells in Large Granular Lymphocyte Leukemia. *J Immunol* 2013;191:3578-93.
 82. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. *Proc Natl Acad Sci U S A* 2004;101:811-6.
 83. Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. *J Clin Oncol* 2009;27:1160-7.
 84. Crnogorac-Jurcevic T, Chelala C, Barry S, et al. Molecular analysis of precursor lesions in familial pancreatic cancer. *PLoS One* 2013;8:e54830.
 85. Hu Z, Fan C, Livasy C, et al. A compact VEGF signature associated with distant metastases and poor outcomes. *BMC Med* 2009;7:9.
 86. De Preter K, Vandesompele J, Heimann P, et al. Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes. *Genome Biol* 2006;7:R84.
 87. Uva P, Aurisicchio L, Watters J, et al. Comparative expression pathway analysis of human and canine mammary tumors. *BMC Genomics* 2009;10:135.
 88. Shimokuni T, Tanimoto K, Hiyama K, et al. Chemosensitivity prediction in esophageal squamous cell carcinoma: novel marker genes and efficacy-prediction formulae using their expression data. *Int J Oncol* 2006;28:1153-62.
 89. Joy A, Ramesh A, Smirnov I, et al. AKT pathway genes

- define 5 prognostic subgroups in glioblastoma. *PLoS One* 2014;9:e100827.
90. Griesinger AM, Josephson RJ, Donson AM, et al. Interleukin-6/STAT3 pathway signaling drives an inflammatory phenotype in Group A ependymoma. *Cancer Immunol Res* 2015;3:1165-74.
 91. Shah MV, Zhang R, Irby R, et al. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. *Blood* 2008;112:770-81.
 92. Yuan SX, Wang J, Yang F, et al. Long noncoding RNA DANCR increases stemness features of hepatocellular carcinoma by derepression of CTNNB1. *Hepatology* 2016;63:499-511.
 93. Tong M, Chan KW, Bao JY, et al. Rab25 is a tumor suppressor gene with antiangiogenic and anti-invasive activities in esophageal squamous cell carcinoma. *Cancer Res* 2012;72:6024-35.
 94. Wei G, Luo H, Sun Y, et al. Transcriptome profiling of esophageal squamous cell carcinoma reveals a long noncoding RNA acting as a tumor suppressor. *Oncotarget* 2015;6:17065.
 95. Gutmann DH, Hedrick NM, Li J, et al. Comparative gene expression profile analysis of neurofibromatosis 1-associated and sporadic pilocytic astrocytomas. *Cancer Res* 2002;62:2085-91.
 96. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. *Oncogene* 2003;22:4918-23.
 97. French PJ, Swagemakers SM, Nagel JH, et al. Gene expression profiles associated with treatment response in oligodendrogliomas. *Cancer Res* 2005;65:11335-44.
 98. Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. *Genome Biol* 2007;8:R131.
 99. Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. *Clin Cancer Res* 2005;11:5730-9.
 100. Yussenko MV, Kuiper RP, Boethe T, et al. High-resolution DNA copy number and gene expression analyses distinguish chromophobe renal cell carcinomas and renal oncocytomas. *BMC Cancer* 2009;9:152.
 101. Cutcliffe C, Kersey D, Huang CC, et al. Clear cell sarcoma of the kidney: up-regulation of neural markers with activation of the sonic hedgehog and Akt pathways. *Clin Cancer Res* 2005;11:7986-94.
 102. Basso K, Margolin AA, Stolovitzky G, et al. Reverse engineering of regulatory networks in human B cells. *Nat Genet* 2005;37:382-90.
 103. Valk PJ, Verhaak RG, Beijnen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med* 2004;350:1617-28.
 104. Dürig J, Bug S, Klein-Hitpass L, et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv (14)(q11q32). *Leukemia* 2007;21:2153-63.
 105. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. *Proc Natl Acad Sci U S A* 2001;98:13790-5.
 106. Talantov D, Mazumder A, Jack XY, et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. *Clin Cancer Res* 2005;11:7234-42.
 107. Grützmann R, Pilarsky C, Ammerpohl O, et al. Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. *Neoplasia* 2004;6:611-22.
 108. Buchholz M, Braun M, Heidenblut A, et al. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. *Oncogene* 2005;24:6626-36.
 109. Detwiller KY, Fernando NT, Segal NH, et al. Analysis of hypoxia-related gene expression in sarcomas and effect of hypoxia on RNA interference of vascular endothelial cell growth factor A. *Cancer Res* 2005;65:5881-9.
 110. Henriquez NV, Forshew T, Tatevossian R, et al. Comparative expression analysis reveals lineage relationships between human and murine gliomas and a dominance of glial signatures during tumor propagation in vitro. *Cancer Res* 2013;73:5834-44.
 111. Romero A, Martín M, Oliva B, et al. Glutathione S-transferase P1 c.313A > G polymorphism could be useful in the prediction of doxorubicin response in breast cancer patients. *Ann Oncol* 2012;23:1750-6.
 112. Stathopoulos GP, Armakolas A. Differences in gene expression between individuals with multiple primary and single primary malignancies. *Int J Mol Med* 2009;24:613-22.
 113. Kim WJ, Kim EJ, Kim SK, et al. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer. *Mol Cancer* 2010;9:3.
 114. Kim YJ, Yoon HY, Kim JS, et al. HOXA9, ISL1 and ALDH1A3 methylation patterns as prognostic markers for nonmuscle invasive bladder cancer: Array-based DNA methylation and expression profiling. *Int J Cancer* 2013;133:1135-42.

115. Abba M, Laufs S, Aghajany M, et al. Look who's talking: deregulated signaling in colorectal cancer. *Cancer Genomics Proteomics* 2012;9:15-25.
116. Ema A, Waraya M, Yamashita K, et al. Identification of EGFR expression status association with metastatic lymph node density (ND) by expression microarray analysis of advanced gastric cancer. *Cancer Med* 2015;4:90-100.
117. Yang C, Zhuang Z, Fliedner SM, et al. Germ-line PHD1 and PHD2 mutations detected in patients with pheochromocytoma/paraganglioma-polycythemia. *J Mol Med* 2015;93:93-104.
118. Gao F, Liang H, Lu H, et al. Global analysis of DNA methylation in hepatocellular carcinoma by a liquid hybridization capture-based bisulfite sequencing approach. *Clin Epigenetics* 2015;7:86.
119. Leja J, Essaghir A, Essand M, et al. Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. *Mod Pathol* 2009;22:261-72.
120. Ding X, Yang Y, Han B, et al. Transcriptomic characterization of hepatocellular carcinoma with CTNNB1 mutation. *PLoS One* 2014;9:e95307.
121. Kadara H, Fujimoto J, Yoo SY, et al. Transcriptomic architecture of the adjacent airway field cancerization in non-small cell lung cancer. *J Natl Cancer Inst* 2014;106:dju004.
122. Rousseaux S, Debernardi A, Jacquiau B, et al. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. *Sci Transl Med* 2013;5:186ra66.
123. Lockwood WW, Chari R, Coe BP, et al. DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers. *Oncogene* 2008;27:4615-24.
124. Smith AP, Hoek K, Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. *Cancer Biol Ther* 2005;4:1018-29.
125. Chandran UR, Ma C, Dhir R, et al. Gene expression profiles of prostate cancer reveal involvement of multiple molecular pathways in the metastatic process. *BMC Cancer* 2007;7:64.
126. Renner M, Wolf T, Meyer H, et al. Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas. *Genome Biol* 2013;14:r137.
127. Grasso CS, Wu YM, Robinson DR, et al. The mutational landscape of lethal castration-resistant prostate cancer. *Nature* 2012;487:239-43.
128. Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. *Nat Commun* 2015;6:6087.
129. Aoyagi K, Minashi K, Igaki H, et al. Artificially induced epithelial-mesenchymal transition in surgical subjects: its implications in clinical and basic cancer research. *PLoS One* 2011;6:e18196.
130. Yu K, Ganesan K, Tan LK, et al. A precisely regulated gene expression cassette potently modulates metastasis and survival in multiple solid cancers. *PLoS Genet* 2008;4:e1000129.
131. Sternberg A, Killick S, Littlewood T, et al. Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. *Blood* 2005;106:2982-91.
132. LaBrecche HG, Nevins JR, Huang E. Integrating factor analysis and a transgenic mouse model to reveal a peripheral blood predictor of breast tumors. *BMC Med Genomics* 2011;4:61.
133. Seok JY, Na DC, Woo HG, et al. A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition. *Hepatology* 2012;55:1776-86.
134. Zhan F, Barlogie B, Arzoumanian V, et al. Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. *Blood* 2007;109:1692-700.
135. Gordon GJ, Rockwell GN, Jensen RV, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. *Am J Pathol* 2005;166:1827-40.
136. Wu H, Chen Y, Liang J, et al. Hypomethylation-linked activation of PAX2 mediates tamoxifen-stimulated endometrial carcinogenesis. *Nature* 2005;438:981-7.
137. Dyrskjot L, Kruhoffer M, Thykjaer T, et al. Gene Expression in the Urinary Bladder A Common Carcinoma in Situ Gene Expression Signature Exists Disregarding Histopathological Classification. *Cancer Res* 2004;64:4040-8.
138. Radvanyi L, Singh-Sandhu D, Gallichan S, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. *Proc Natl Acad Sci U S A* 2005;102:11005-10.
139. Kimchi ET, Posner MC, Park JO, et al. Progression of Barrett's metaplasia to adenocarcinoma is associated with the suppression of the transcriptional programs of epidermal differentiation. *Cancer Res* 2005;65:3146-54.
140. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *J Clin Epidemiol* 2009;62:1006-12.